Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Long-Term Debt Repayments (2016 - 2021)

Pediatrix Medical (MD) has disclosed Long-Term Debt Repayments for 13 consecutive years, with $690000.0 as the latest value for Q3 2021.

  • On a quarterly basis, Long-Term Debt Repayments rose 179.35% to $690000.0 in Q3 2021 year-over-year; TTM through Sep 2021 was $2.5 million, a 482.91% increase, with the full-year FY2020 number at $1.2 million, changed N/A from a year prior.
  • Long-Term Debt Repayments was $690000.0 for Q3 2021 at Pediatrix Medical, up from $434000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $728000.0 in Q4 2020 to a low of -$996000.0 in Q4 2018.
  • A 5-year average of $271529.4 and a median of $315000.0 in 2018 define the central range for Long-Term Debt Repayments.
  • Peak YoY movement for Long-Term Debt Repayments: crashed 2791.89% in 2018, then soared 352.04% in 2020.
  • Pediatrix Medical's Long-Term Debt Repayments stood at $37000.0 in 2017, then plummeted by 2791.89% to -$996000.0 in 2018, then soared by 90.16% to -$98000.0 in 2019, then soared by 842.86% to $728000.0 in 2020, then dropped by 5.22% to $690000.0 in 2021.
  • Per Business Quant, the three most recent readings for MD's Long-Term Debt Repayments are $690000.0 (Q3 2021), $434000.0 (Q2 2021), and $672000.0 (Q1 2021).